Jubilant Pharmova Q2 Review: Nirmal Bang Raises Target Price, Bets On H2 Margin Recovery
NDTV

Nirmal Bang raised its target price for Jubilant Pharmova, citing expected margin recovery and earnings visibility.
Nirmal Bang believes the FY28 ramp-up in Line 3, Line 4, and the PET network,
together with SPECT normalisation, gives enough visibility for Jubilant
Pharmova's stronger earnings.






